Stent Thrombosis
41
7
8
29
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
2.4%
1 terminated out of 41 trials
96.7%
+10.2% vs benchmark
24%
10 trials in Phase 3/4
24%
7 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (41)
ABLUMINUS NP Polymer Free Sirolimus-Eluting Stent Registry at Geneva University Hospitals (ABLUMINUS-GVA)
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
Flow Patterns and Stent Thrombosis
Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance
TADCLOT- a Double Blind Randomized Controlled Trial
Mini-Crush Or Controlled Balloon-Crush For True Coronary Bifurcation Lesions
TISSARA Trial: Ticagrelor Intervention to Reduce Stent Thrombosis and Acute MI Risk
SIROOP Registry - a Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated with SIROlimus or Paclitaxel Eluting Balloon Catheters
COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease
Leaders Free III: BioFreedom™ Clinical Trial
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
Evaluating Pharmacogenomic Variants for Cardiology Therapeutics
Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia
Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects
Glasgow Natural History Study Of Covered Coronary Interventions
PTRG-DES Consortium
Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors
Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO)
CONNECT DES Registrty
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting